Clinical use of heparin fractions, fragments, and heparinoids.
H L
HL
Messmore
D000818:Animals; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates; D002986:Clinical Trials as Topic; D003871:Dermatan Sulfate; D005170:Factor X / Q000037:antagonists & inhibitors; D015951:Factor Xa; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006496:Heparinoids / Q000627:therapeutic use; D006497:Heparan Sulfate; D006801:Humans; D007700:Kinetics; D008970:Molecular Weight; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000139:chemically induced / Q000175:diagnosis; D013927:Thrombosis / Q000517:prevention & control; D014511:Uremia / Q000628:therapy
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005170:Factor X; D015951:Factor Xa; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid